ROCKVILLE, Md., July 26,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a conference call on Wednesday, August 2, 2023, at 4:30 p.m. ET to discuss its financial results for
the quarter ended June 30, 2023, and
recent operational highlights.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company's investor website approximately two hours after the call's
conclusion. Those who plan on participating are advised to join 15
minutes prior to the start time.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from its internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contact:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-2-to-discuss-second-quarter-2023-financial-results-and-recent-operational-highlights-301885977.html
SOURCE REGENXBIO Inc.